

Attorney's Docket No.: 09531-005001

Client's Ref. No.: 97141

**OFFICIAL COMMUNICATION****FACSIMILE****FOR THE PERSONAL ATTENTION OF:****HOLLY SCHNIZER, EXAMINER****FAX RECEIVED****AUG 13 2002****GROUP 1600****GROUP 1653 FAX NO: (703) 308-4242**

Number of pages including this page 8

Applicant : Gary L. Nelsestuen  
Serial No. : 09/302,239  
Filed : April 29, 1999

Art Unit : 1653  
Examiner : H. Schnizer

**OFFICIAL****FACSIMILE COMMUNICATION**

Title : MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES


Commissioner for Patents  
Washington, DC 20231

Madam:

Attached to this facsimile communication cover sheet is the Response, faxed this 12<sup>th</sup> day of August, 2002, to Group 1653, the United States Patent and Trademark Office.

Respectfully submitted,

Date: August 12<sup>th</sup>, 2002

  
Monica McCormick Graham, Ph.D.  
Reg. No. 42,600

Fish & Richardson P.C., P.A.  
60 South Sixth Street  
Suite 3300  
Minneapolis, MN 55402  
Telephone: (612) 335-5070  
Fax: (612) 288-9696

60099278.doc

**NOTE: This facsimile is intended for the addressee only and may contain privileged or confidential information. If you have received this facsimile in error, please immediately call us collect at (612) 335-5070 to arrange for its return. Thank you.**

Attorney's Docket No.: 09531-005001 / 97141

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gary L. Nelsestuen

Art Unit : 1653

Serial No. : 09/302,239

Examiner : H. Schnizer

Filed : April 29, 1999

Title : MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES

BOX AF

Commissioner for Patents

Washington, DC 20231

OFFICIAL

AMENDMENT AND RESPONSE AFTER FINAL

In response to the action mailed June 18, 2002, please amend the application as follows:

In the claims:

Please cancel claims 15 and 18-22.

Please amend claims 1 and 3-14 as follows:

OK  
TO ENTER  
HS 9-3-02

-- 1. (Three Times Amended) A Factor VII or Factor VIIa polypeptide comprising a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native Factor VII or Factor VIIa polypeptide, said modified GLA domain comprising at least one amino acid substitution at residue 11 (corresponding to residue 10 of SEQ ID NO:3 or SEQ ID NO:4) or 29 (corresponding to residue 28 of SEQ ID NO:3 or SEQ ID NO:4).

C1

3. (Twice Amended) The polypeptide of claim 1, wherein a glutamine, a glutamic acid, an aspartic acid, or an asparagine residue is substituted at residue 11 (corresponding to residue 10 of SEQ ID NO:3 or SEQ ID NO:4).

4. (Amended) The polypeptide of claim 3, wherein a glutamine residue is substituted at residue 11 (corresponding to residue 10 of SEQ ID NO:3 or SEQ ID NO:4).

## CERTIFICATE OF TRANSMISSION BY FACSIMILE

I hereby certify that this correspondence is being transmitted by facsimile to the Patent and Trademark Office on the date indicated below.

August 12, 2002  
Date of Transmission  
Signature  
Kathryn J. Sanderson  
Typed or Printed Name of Person Signing Certificate